Discover. Oncology最新文献

{"title":"Efficacy of astragalus polysaccharides (PG2) in alleviating chemotherapy-induced fatigue in gynecologic cancer: a retrospective cohort study.","authors":"Chia-Ching Chang, Yi-Liang Lee, Chih-Hsiang Yin, Cheng-Chang Chang, Yi-Hsin Lin","doi":"10.1007/s12672-025-03120-y","DOIUrl":"10.1007/s12672-025-03120-y","url":null,"abstract":"<p><strong>Background: </strong>Cancer related fatigue (CRF) is a common and debilitating side effect among gynecologic cancer patients undergoing chemotherapy. Astragalus polysaccharides (PG2), an immunomodulatory drug, has shown promise in relieving CRF. This study aimed to evaluate the effectiveness of PG2 in managing CRF in gynecologic cancer patients.</p><p><strong>Methods: </strong>This retrospective cohort study was performed at the Department of Obstetrics & Gynecology, Tri-Service General Hospital from December 2015 to December 2022. Of 53 patients included, 40 received PG2 with chemotherapy, while 13 received chemotherapy alone. Outcomes included CRF severity and HRQL, assessed via Brief Fatigue Inventory (BFI) and Functional Assessment of Cancer Therapy-General 7 (FACT-G7), plus safety profiles.</p><p><strong>Results: </strong>PG2-treated patients showed a statistically significant reduction in CRF severity, as reflected by lower BFI (p < 0.001). The PG2 group showed trends toward improved HRQL and reduced appetite loss, though not statistically significant (p > 0.05). PG2's safety profile aligned with the control group, showing no increase in grade 3/4 toxicities.</p><p><strong>Conclusion: </strong>The study concludes that PG2 shows promise as an adjunct therapy in the management of CRF among patients with gynecologic cancer receiving chemotherapy. However, the findings highlight the need for additional prospective, randomized controlled trials to rule out the risk of bias and ascertain PG2's full therapeutic potential in oncology supportive care.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1322"},"PeriodicalIF":2.8,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SPDL1 overexpression was associated with poor prognosis and immune status in HCC through in vitro experiment and bioinformatics analysis.","authors":"Ying-Ming Xu, Bo-Hua You, Ming Chen, Tian-Ping Xiong, Lin Shi, Qin Wei, Zhong-An Wang","doi":"10.1007/s12672-025-03089-8","DOIUrl":"10.1007/s12672-025-03089-8","url":null,"abstract":"<p><strong>Background: </strong>Numerous studies have established a strong link between the overexpression of spindle apparatus coiled-coil protein 1 (SPDL1) and cancer progression. However, the role of SPDL1 in hepatocellular carcinoma (HCC) remains unconfirmed.</p><p><strong>Methods: </strong>The level of SPDL1 in HCC and its potential associations with prognosis and clinicopathological features were analyzed using TCGA and XENA databases. Bioinformatics and in vitro approaches were employed to investigate the biological functions, signaling pathways, and protein networks involving SPDL1. Additionally, correlation analyses were performed to explore the relationship between SPDL1 and the immune microenvironment.</p><p><strong>Results: </strong>SPDL1 was overexpressed in HCC. Its overexpression correlated negatively with T stage, pathological stage, tumor status, age, body weight, differentiation, alpha-fetoprotein levels, vascular invasion, diagnosis, and poor prognosis in patients with HCC, positioning it as a risk factor for adverse outcomes. High-risk scores related to SPDL1 expression were significantly linked to poor prognosis in patients with HCC. Suppression of SPDL1 expression inhibited HCC cell proliferation, invasion, and migration. Furthermore, SPDL1 expression showed significant correlations with Th2 cells (r = 0.628), T helper cells (r = 0.296), Th17 cells (r = -0.422), neutrophils (r = -0.408), dendritic cells (r = -0.358), cytotoxic cells (r = -0.310), plasmacytoid dendritic cells (r = -0.275), and other immune cell populations in HCC.</p><p><strong>Conclusion: </strong>Overexpression of SPDL1 is associated with poor prognosis and the immune microenvironment in HCC. Inhibition of SPDL1 expression can suppress tumor growth and metastasis, suggesting that SPDL1 may serve as a potential therapeutic target for HCC treatment.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1310"},"PeriodicalIF":2.8,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The state of cancer research and its association with the cancer burden in Ecuador: a bibliometric study.","authors":"Santiago D Padilla-Sánchez, Isabel Espinosa, Ivan Sisa","doi":"10.1007/s12672-025-03168-w","DOIUrl":"10.1007/s12672-025-03168-w","url":null,"abstract":"<p><strong>Purpose: </strong>Cancer has emerged as a major public health concern in Ecuador, reflecting global trends. Thus, it is imperative to understand the country´s cancer research landscape. We aim to conduct a bibliometric analysis of Ecuadorian cancer research publications from 2008 to 2021 to identify research trends, institutional contributions, international collaborations, and the association with the national cancer burden.</p><p><strong>Methods: </strong>Articles were retrieved from Scopus, PubMed, and LILACS databases. Descriptive statistics and chi-square tests were employed to analyze different bibliometric indicators.</p><p><strong>Results: </strong>A marked increase in cancer-related research output was observed, particularly after 2014. The most common study designs were case reports (n = 244, 30.7%), cross-sectional studies (n = 174, 21.9%) and review articles (n = 131, 16.5%). Universities were the main contributors to national cancer research, accounting for 32.4% (n = 256) of all publications, with private institutions more frequently publishing in higher-ranked journals. Collaborative efforts between universities and hospitals represented 25.3% (n = 200) of publications, though 45.1% of these were indexed in the lowest SCImago Journal Rank quartile (Q4). The most frequently studied cancer types by body location/system were gastrointestinal, gynecologic, and breast cancer. This trend contrasts with national cancer statistics reported in 2022, in which the most common cancer types were breast, prostate (genitourinary), and stomach (gastrointestinal) cancers.</p><p><strong>Conclusion: </strong>Our study provides a comprehensive overview of oncology research in Ecuador over a 14-year period. While research output has increased, there remains a need to enhance research quality and ensure closer alignment with the country's primary cancer burdens to better inform national cancer control strategies.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1307"},"PeriodicalIF":2.8,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a prognostic nomogram for gastric GIST patients under 65 years of age.","authors":"Yifan Cheng, Shuyang Gao, Zhen Tian, Shuai Zhao, Ruiqi Li, Jiajie Zhou, Yayan Fu, Qiannan Sun, Daorong Wang","doi":"10.1007/s12672-025-03092-z","DOIUrl":"10.1007/s12672-025-03092-z","url":null,"abstract":"<p><strong>Background: </strong>Gastric gastrointestinal stromal tumor (GIST) is the most common sarcoma of the digestive tract. Due to the fact that younger patients often present with more aggressive disease and exhibit different treatment responses compared to older patients, this study aimed to develop models to predict overall survival (OS) and cancer-specific survival (CSS) in postoperative gastric GIST patients under the age of 65, thereby aiding in the creation of optimal, individualized treatment strategies.</p><p><strong>Methods: </strong>We first reviewed demographic and clinicopathological characteristics data from 1990 to 2021 of patients diagnosed with GIST in the Surveillance, Epidemiology, and End Results (SEER) database. Subsequently, we examined the data of the external validation cohort from Northern Jiangsu People's Hospital. Utilizing Lasso analysis and multivariate Cox regression analyses, we confirmed the independent risk factors and created nomograms for the prediction of OS and CSS of postoperative gastric GIST patients under age 65, followed by validation with the external validation cohort. To assess the predictive ability of these nomograms, we employed the concordance index (C-index), calibration curves, time-dependent receiver operating characteristic (ROC), and decision curve analysis (DCA).</p><p><strong>Results: </strong>A total of 735 eligible gastric GIST patients from SEER were enrolled in the training cohort and 113 patients from Northern Jiangsu People's Hospital were enrolled in the validation cohort. 3 factors (grade, M stage, mitotic index) associated with OS and 4 factors (grade, T stage, M stage, mitotic index) associated with CSS were included in the model respectively. In the training cohort, the C-index was 0.706 (95% CI = 0.645-0.767) for OS and 0.880 (95% CI = 0.845-0.915) for CSS, while in the validation cohort, the C-index was 0.718 (95% CI = 0.618-0.818) for OS and 0.805 (95% CI = 0.715-0.895) for CSS. Calibration curves and ROCs for 3-, 5-, and 8-year OS and CSS showed high discrimination and calibration. DCA results showed that the nomograms had clinical value in predicting OS and CSS in gastric GIST patients.</p><p><strong>Conclusion: </strong>Our nomograms satisfactorily predicted OS and CSS in postoperative gastric GIST patients under age 65, which could assist clinicians in evaluating postoperative status, guiding subsequent treatments, and improving patient prognosis.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1313"},"PeriodicalIF":2.8,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IPSS-M outperforms IPSS-R in prognostic stratification and guides effective interventions for very High-Risk myelodysplastic syndrome patients undergoing allogeneic hematopoietic stem cell transplantation.","authors":"Huixian Wu, Shuang Li, Jun Yang, Yu Cai, Huiying Qiu, Chongmei Huang, Yin Tong, Kun Zhou, Jiahua Niu, Xinxin Xia, Ying Zhang, Xiaowei Xu, Chang Shen, Baoxia Dong, Liping Wan, Xianmin Song","doi":"10.1007/s12672-025-03155-1","DOIUrl":"10.1007/s12672-025-03155-1","url":null,"abstract":"<p><p>Allogeneic hematopoietic stem cell transplantation represents a curative modality for patients with myelodysplastic syndrome (MDS), yet relapse risk persists. The prognostic performances of the Revised International Prognostic Scoring System (IPSS-R) and the Molecular International Prognostic Scoring System (IPSS-M) for 129 MDS patients undergoing allogeneic peripheral blood stem cell transplantation (allo-PBSCT) were evaluated. Using IPSS-M, 29.5% of patients were reclassified to a higher risk and 14.0% to a lower risk compared to IPSS-R. The two-year recurrence-free survival (RFS) and overall survival (OS) post-transplant were similar across IPSS-R groups, but significantly lower in the very-high risk category with IPSS-M (P = 0.005 for RFS; P = 0.014 for OS). Multivariate analysis revealed that patient age (P = 0.009, P = 0.017), very-high risk category in IPSS-M (P = 0.003, P = 0.001), and KPS score (P = 0.034, P = 0.055) were independent factors for OS and RFS. Only very-high risk category in IPSS-M was the independent factor affecting cumulative incidence of relapse (P = 0.003). Prophylactic interventions for relapse significantly decreased the risk of relapse (P = 0.003) and increased the survival of patients in the very-high risk category (P = 0.002 for OS, P = 0.006 for RFS). The study suggested that the IPSS-M system could identify the high relapse risk patients post-transplant who may benefit from early prophylactic interventions.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1315"},"PeriodicalIF":2.8,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the role of PANoptosis related genes in the prognosis of oral squamous cell carcinoma subtypes based on multi-omics analysis.","authors":"Yang Liu, Lingdu Wen, Lijuan Yan, Zifeng Cui","doi":"10.1007/s12672-025-03154-2","DOIUrl":"10.1007/s12672-025-03154-2","url":null,"abstract":"<p><strong>Background: </strong>Oral squamous cell carcinoma (OSCC) has a poor prognosis. PANoptosis, involving apoptosis, pyroptosis, and necroptosis, may be linked to cancer. Identifying OSCC subtypes and creating prognostic models based on PANoptosis-related genes (PRGs) can improve diagnosis and treatment.</p><p><strong>Methods: </strong>RNA-seq and DNA methylation data from OSCC patients in The Cancer Genome Atlas (TCGA) were analyzed. Clustering algorithms identified OSCC subtypes, which were examined for differences in spatial distribution, biological pathways, drug sensitivity, prognosis, and immune infiltration. Prognostic genes were identified using Cox regression analyses. Mendelian randomization identified genes linked to OSCC. Drug sensitivity and tumor mutation load were assessed. Single-cell RNA sequencing (scRNA-seq) data explored the expression of prognostic genes. qRT-PCR verified gene expression.</p><p><strong>Results: </strong>OSCC subtypes based on PRGs showed differences in prognosis, immunity, drug sensitivity, and pathways. Pantothenate and CoA biosynthesis pathways varied among subtypes, with immune cells highly infiltrated in CS1. The prognostic model highlighted differences in prognosis and immunotherapy response. BAK1 was causally linked to OSCC risk. Combining TMB score improved patient stratification. qRT-PCR confirmed differences in gene expression between control and OSCC groups. Monocytes were identified as high-scoring cells, with TGFb and MIF pathways important in cell communication.</p><p><strong>Conclusion: </strong>Two OSCC subtypes and eight prognostic genes (TGFBR3, CYCS, HDAC9, PLK1, GSDMB, HSPA4, BAK1, SOD2) were identified, aiding in treatment and risk stratification. BAK1 is causally linked to OSCC risk.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1305"},"PeriodicalIF":2.8,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zwilch kinetochore protein affects the prognosis of cancer patients by participating in cell proliferation, enhancing cell communication, and reshaping the tumor microenvironment.","authors":"Long Yao, Lianpo Liu, Jinsong Wu, Yunlong Huang, Renquan Zhang, Haoxue Zhang","doi":"10.1007/s12672-025-02981-7","DOIUrl":"10.1007/s12672-025-02981-7","url":null,"abstract":"<p><strong>Background: </strong>Zwilch Kinetochore Protein(ZWILCH) has been reported to prevent cells from prematurely exiting mitosis. However, the underlying mechanisms or involvement of ZWILCH in the tumor immune microenvironment in various cancers remain largely unknown.</p><p><strong>Methods: </strong>Generalized dysregulation of ZWILCH was observed through the whole transcriptome analysis in this study. The spatial transcriptome analysis was utilized to identify expressed regions of ZWILCH. Next, cells that mainly expressed ZWILCH in the tumor microenvironment were determined using the single-cell transcriptome analysis. Also, the \"cellchat\" R package was applied to estimate the effect of ZWILCH on malignant cell communication. Combining multiple analytic approaches including GSEA, GSVA, KEGG enrichment analysis, and Aucell, with TCPA functional protein data, Genome-wide CRISPR screening, potential functions of ZWILCH and the pathways in which ZWILCH participated were thoroughly exploited. Univariate Cox regression analysis calculated the association between ZWILCH and cancer patients' adverse outcomes.</p><p><strong>Results: </strong>ZWILCH is universally highly expressed in tumors. The spatial transcriptome analysis showed that ZWILCH overexpression comes from the tumoral region or mixed tumoral region. At the single-cell level, ZWILCH is chiefly expressed by malignant cells and proliferative T cells. The expression of ZWILCH mRNA is positively correlated with cell proliferation, repair of DNA damage, and cell cycle score. Plenty of metabolic pathways are inhibited in patients with high expression of ZWILCH. Moreover, after ZWILCH knockout, a large number of cancer cell lines are stagnated, inhibited, or died. Additionally, the malignant cells with positive expression of ZWILCH have a stronger ability for cell communication. In short, ZWILCH is meant to be a risk factor for clinical outcomes of multiple tumors.</p><p><strong>Conclusions: </strong>ZWILCH is a promising therapeutic target that influences patient prognosis by participating in cell proliferation, cell communication, and reshaping the tumor microenvironment across different cancers.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1308"},"PeriodicalIF":2.8,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypoxia- and lactate metabolism-associated prognostic and therapeutic signature in pancreatic cancer.","authors":"Chen-Hui Zhang, An-Qi Huang, Cang-Chang Shi, Zhi-Jia Jiang, Hao Yao, Jin-Jin Sun","doi":"10.1007/s12672-025-02873-w","DOIUrl":"10.1007/s12672-025-02873-w","url":null,"abstract":"<p><strong>Background: </strong>Hypoxia and lactate metabolism products are critical components of the tumor microenvironment in pancreatic cancer (PC), influencing tumor invasiveness, metastasis, and treatment resistance. This study aims to explore the role of hypoxia- and lactate metabolism-related genes (HLRGs) in predicting overall survival and guiding treatment for PC patients.</p><p><strong>Methods: </strong>Gene expression and clinical data from PC patients were obtained from TCGA, ICGC, and GEO. Normal pancreatic tissue data were sourced from GTEx. Differential expression analysis was performed on the merged TCGA-PAAD and GTEx cohorts to identify differentially expressed genes (DEGs). We performed an intersection analysis between the DEGs and the HLRGs obtained from the MsigDB database to identify the DEGs associated with hypoxia and lactate metabolism in PC. A prognostic model was developed using random survival forests, Cox regression, and LASSO analysis in the TCGA-PAAD cohort. The model was externally validated in the ICGC-PACA and GSE85916 cohorts. Risk stratification was performed, and the differences between subgroups in tumor mutational burden, immune microenvironment, and drug response were analyzed. RT-qPCR validated the key genes expression differences.</p><p><strong>Results: </strong>A prognostic model based on HLRGs (SLC7A7, PYGL, HS3ST1, DDIT4, CYP27A1, ANKZF1, COL5A1) was established. High-risk patients exhibited worse prognosis, higher tumor mutational burden, and better response to anti-PD-L1 therapy, while low-risk patients exhibited higher immune infiltration and increased chemotherapy sensitivity. RT-qPCR confirmed that SLC7A7 and COL5A1 were upregulated, while ANKZF1 was downregulated in PC.</p><p><strong>Conclusions: </strong>We developed an HLRGs-based prognostic model that predicts overall survival and guides treatment strategies, contributing to precision therapy in PC.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1317"},"PeriodicalIF":2.8,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the potential value of SRC in pan cancer based on bioinformatics methods.","authors":"Liyin Huang, Yanwen Lu, Lei Yi, Yuxin Zhao, Tao Si, Mingmin Zhang","doi":"10.1007/s12672-025-02402-9","DOIUrl":"10.1007/s12672-025-02402-9","url":null,"abstract":"<p><strong>Background: </strong>Tyrosine-Protein Kinase Src (SRC), a non-receptor tyrosine kinase encoded by the Src gene, plays a crucial role in cell growth, division, migration, and survival signaling pathways. Dysregulation of SRC expression and activity is associated with advanced stages of several human cancers and poor prognosis. However, the prognostic value of SRC across multiple cancers and its involvement in immune response remain unclear. Therefore, this study aimed to investigate the relationship between SRC expression levels and cancer patient prognosis, as well as its potential impact on the immune microenvironment.</p><p><strong>Methods: </strong>In this study, we utilized the Sangerbox database to investigate the differential expression of SRC in various types of cancer tumors and adjacent normal tissues. Survival outcomes of SRC expression levels in pan cancer were analyzed by Cox risk ratio and Kaplan Meier analysis. We further explored the relationship between SRC expression and immune regulatory genes, tumor mutation load, microsatellite instability, and the immune microenvironment of pan cancer using the Sangerbox database.</p><p><strong>Results: </strong>Compared to normal tissues, SRC expression is upregulated in various tumor tissues. SRC is significantly correlated with OS and in tumors such as LIHC and PRAD. Furthermore, SRC expression is significantly associated with mutation burden and microsatellite instability in tumors such as LUAD and COAD. In addition, SRC expression is related to the abundance of infiltrating immune cells in tumors such as LIHC and PRAD. These findings suggest that SRC may serve as a potential prognostic biomarker and therapeutic target for various cancers, and may be associated with the immune microenvironment of tumors.</p><p><strong>Conclusion: </strong>Our results suggest that SRC may play a role in regulating immune infiltration and impacting the prognosis of cancer patients, highlighting its potential as a therapeutic target and biomarker for various cancers.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1309"},"PeriodicalIF":2.8,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nomogram predicting overall survival in hospitalized cervical cancer patients in Mato Grosso, Brazil.","authors":"Sancho Pedro Xavier, Audêncio Victor, Noemi Dreyer Galvão, Ageo Mario Cândido da Silva","doi":"10.1007/s12672-025-02380-y","DOIUrl":"10.1007/s12672-025-02380-y","url":null,"abstract":"<p><strong>Introduction: </strong>Nomograms are widely recognized as effective predictive tools for estimating cancer prognosis, providing a personalized and practical approach to support clinical decision-making. This study aimed to develop and validate a nomogram for predicting the survival of hospitalized patients with cervical cancer (CC).</p><p><strong>Methods: </strong>Eligible data were obtained from the Hospital Information System (SIH) of Brazil's Unified Health System (SUS) in Mato Grosso State, covering the period from 2011 to 2023. A nomogram was constructed based on a previously published multivariable Cox regression model. Model performance was assessed using Harrell's concordance index (C-index) and a calibration curve.</p><p><strong>Results: </strong>The developed nomogram achieved a C-index of 0.817, indicating good discriminative ability. The most significant predictors included the type of medical procedure performed, the need for ICU admission, and hospital costs. The calibration curve demonstrated good agreement between actual and predicted 30-day survival probabilities.</p><p><strong>Conclusion: </strong>A useful clinical nomogram was developed to calculate the probability of survival for hospitalized patients with CC. The model demonstrated excellent performance, assisting healthcare professionals in selecting more appropriate treatments and providing accurate prognostic predictions for both clinical and research contexts.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1312"},"PeriodicalIF":2.8,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}